Shweta Kumari Agrawal

Dr. Shweta Kumari Agrawal


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Process Biochemistry
Verified
Journal Article
Closed access
SAShweta Kumari Agrawal
Shweta Kumari Agrawal
Devayani R. TipreDevayani R. Tipre
Devayani R. Tipre
BPBhavesh Patel
Bhavesh Patel
SDShailesh Dave
Shailesh Dave


5 April 2017
Verified
Book Chapter
Closed access
PDF file
SAShweta Kumari Agrawal
Shweta Kumari Agrawal
DTDevayani Tipre
Devayani Tipre
BPBhavesh Patel
Bhavesh Patel
SDShailesh Dave
Shailesh Dave

12 March 2024 in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
KSKhushboo Sharma
Khushboo Sharma
UPUmesh Panwar
Umesh Panwar
MMMaddala Madhavi
Maddala Madhavi
IJIsha Joshi
Isha Joshi
ICIshita Chopra
Ishita Chopra
SSSanjeev Kumar Singh
Sanjeev Kumar Singh
Background: The current study recognizes the significance of estrogen receptor alpha (ERα) as a member of the nuclear receptor protein family, which holds a central role in the pathophysiology of breast cancer. ERα serves as a valuable prognostic marker, with its established relevance in predicting disease outcomes and treatment responses. Methods: In this study, computational methods are utilized to search for suitable drug-like compounds that demonstrate analogous ligand binding kinetics to ERα. Results: Docking-based simulation screened out the top 5 compounds - ZINC13377936, NCI35753, ZINC35465238, ZINC14726791, and NCI663569 against the targeted protein. Further, their dynamics studies reveal that the compounds ZINC13377936 and NCI35753 exhibit the highest binding stability and affinity. Conclusion: Anticipating the competitive inhibition of ERα protein expression in breast cancer, we envision that both ZINC13377936 and NCI35753 compounds hold substantial promise as potential therapeutic agents. These candidates warrant thorough consideration for rigorous In vitro and In vivo evaluations within the context of clinical trials. The findings from this current investigation carry significant implications for the advancement of future diagnostic and therapeutic approaches for breast cancer.

1 October 2011 in Indian Journal Of Applied Research
Verified
Journal Article
Closed access
PRPragya Rathore
Pragya Rathore
NPNandini Phanse
Nandini Phanse
SAShweta Kumari Agrawal
Shweta Kumari Agrawal

1 June 2010
Verified
Conference Paper
Open access
ADAbhik Das
Abhik Das
SAShweta Kumari Agrawal
Shweta Kumari Agrawal
SVSriram Vishwanath
Sriram Vishwanath
This paper presents the concept of incremental traceback for determining changes in the trace of a network as it evolves with time. A distributed algorithm, based on the methodology of algebraic traceback developed by Dean et al., is proposed that can determine a path of d nodes using O(d) marked packets, and subsequently determine the changes in it using O(log d) marked packets. The algorithm is established to be order-wise optimal, i.e. no other distributed algorithm can determine changes in the path topology using lesser order of bits (or marked packets). The algorithm is shown to have a computational complexity of O(d log d), which is significantly less than that of any existing non-incremental algorithm for algebraic traceback. The extension of the traceback mechanism to systems deploying network coding is also considered.